POTOMAC, MD / ACCESS Newswire / April 8, 2026 / IGC Pharma, Inc. (NYSE:IGC) (&#34;IGC&#34; or the &#34;Company&#34;), a clinical-stage biotechnology company with its lead program currently in a Phase 2 CALMA clinical trial evaluating

<p><strong id="dateline">POTOMAC, MD / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / April 8, 2026 / </strong><strong>IGC Pharma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/IGC">IGC</a>) ("IGC" or the "Company"),</strong> a clinical-stage biotechnology company with its lead program currently in a Phase 2 CALMA clinical trial evaluating IGC-AD1 for Alzheimer's-related agitation today announced that Ascendiant Capital Markets has issued an updated equity research report on the Company, raising its price target to $5.25 per share.</p><p>The research report entitled, "Reports Q3. We believe more positive clinical data and progress in 2026 to be strong catalysts for stock. Raising P/T to $5.25" can be obtained directly from Ascendiant Capital Markets <a rel="nofollow" href="https://pr.report/ki8p">Link</a>.</p><p>All reports on IGC Pharma prepared by analysts represent the views of those analysts and are not necessarily those of IGC Pharma. IGC is not responsible for the content, accuracy, or timelines provided by analysts. By referring to these analysts or distributing their opinions, IGC does not in any way commit itself to the validity of such information, conclusions, or recommendations.</p><p><strong>About IGC Pharma (dba IGC):</strong></p><p><a rel="nofollow" href="https://pr.report/8pdw">IGC Pharma</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/IGC">IGC</a>) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a therapy currently in a Phase 2 trial (<a rel="nofollow" href="https://pr.report/8pdx">CALMA</a>) for agitation in Alzheimer's dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize <a rel="nofollow" href="https://pr.report/ewjs">clinical trials</a>, and enhance patient targeting. With a complete patent portfolio and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.</p><p><strong>Forward-Looking Statements:</strong></p><p>This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 27, 2025, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur. IGC Pharma, Inc. assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.</p><p><strong>Contact Information:</strong><br/>Walter Frank / John Nesbett<br/>IMS Investor Relations<br/><a rel="nofollow" href="mailto:igc@imsinvestorrelations.com">igc@imsinvestorrelations.com</a><br/>(203) 972-9200</p><p><strong>SOURCE:</strong> IGC Pharma, Inc.</p><br/><br/>View the original <a href='https://www.accessnewswire.com/newsroom/en/biotechnology/ascendiant-capital-markets-raises-igc-pharma-price-target-to-5.25-citing-clinical-pro-1155969'>press release</a> on ACCESS Newswire<br/><br/>
      <img src="https://app.accessnewswire.com/img.ashx?id=1155969" width="0" height="0"/>

Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts

IGC Pharma's Price Target Increased to $5.25 by Ascendiant Capital Markets

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>POTOMAC, MD / ACCESS Newswire / April 8, 2026 / IGC Pharma, Inc. (NYSE:IGC) (&amp;#34;IGC&amp;#34; or the &amp;#34;Company&amp;#34;), a clinical-stage biotechnology company with its lead program currently in a Phase 2 CALMA clinical trial evaluating</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Ascendiant Capital Markets has raised IGC Pharma&#039;s price target to $5.25, citing expected positive clinical data for IGC-AD1 in Alzheimer&#039;s trials. This potential catalyst could drive investor interest and stock performance throughout 2026 as the company progresses with its innovative therapies.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>IGC Pharma&#039;s price target raised to $5.25 by Ascendiant Capital Markets.</li><li>Positive clinical data expected to drive stock momentum in 2026.</li><li>IGC-AD1 is in Phase 2 trials for Alzheimer&#039;s-related agitation.</li><li>Company leverages AI for drug discovery and clinical optimization.</li><li>Risks include regulatory approvals and unforeseen developments.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Ascendiant Capital Markets (N/A)</strong>: Initiated a price target increase, signaling confidence in IGC&#039;s potential.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This news falls under Corporate Developments, reflecting advancements in IGC&#039;s clinical trials and market expectations which are likely to influence investor sentiment and stock performance.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Positive clinical trial results could significantly boost IGC&#039;s stock price.</li><li>Improved investor sentiment driven by Ascendiant&#039;s price target revision.</li><li>Regulatory approvals or setbacks could create volatility in IGC&#039;s share price.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Ascendiant raised IGC&#039;s price target to $5.25 on April 8, 2026.</li><li>IGC-AD1 is in a Phase 2 CALMA trial for Alzheimer&#039;s agitation.</li><li>IGC Pharma is focused on drug development using AI technologies.</li><li>The company has a complete patent portfolio.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>IGC offers a favorable investment opportunity with a target price of $5.25 within 12 months.</p>
  </section>
</section>


<p><strong id="dateline">POTOMAC, MD / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / April 8, 2026 / </strong><strong>IGC Pharma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/IGC">IGC</a>) ("IGC" or the "Company"),</strong> a clinical-stage biotechnology company with its lead program currently in a Phase 2 CALMA clinical trial evaluating IGC-AD1 for Alzheimer's-related agitation today announced that Ascendiant Capital Markets has issued an updated equity research report on the Company, raising its price target to $5.25 per share.</p><p>The research report entitled, "Reports Q3. We believe more positive clinical data and progress in 2026 to be strong catalysts for stock. Raising P/T to $5.25" can be obtained directly from Ascendiant Capital Markets <a rel="nofollow" href="https://pr.report/ki8p">Link</a>.</p><p>All reports on IGC Pharma prepared by analysts represent the views of those analysts and are not necessarily those of IGC Pharma. IGC is not responsible for the content, accuracy, or timelines provided by analysts. By referring to these analysts or distributing their opinions, IGC does not in any way commit itself to the validity of such information, conclusions, or recommendations.</p><p><strong>About IGC Pharma (dba IGC):</strong></p><p><a rel="nofollow" href="https://pr.report/8pdw">IGC Pharma</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/IGC">IGC</a>) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a therapy currently in a Phase 2 trial (<a rel="nofollow" href="https://pr.report/8pdx">CALMA</a>) for agitation in Alzheimer's dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize <a rel="nofollow" href="https://pr.report/ewjs">clinical trials</a>, and enhance patient targeting. With a complete patent portfolio and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.</p><p><strong>Forward-Looking Statements:</strong></p><p>This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 27, 2025, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur. IGC Pharma, Inc. assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.</p><p><strong>Contact Information:</strong><br/>Walter Frank / John Nesbett<br/>IMS Investor Relations<br/><a rel="nofollow" href="mailto:igc@imsinvestorrelations.com">igc@imsinvestorrelations.com</a><br/>(203) 972-9200</p><p><strong>SOURCE:</strong> IGC Pharma, Inc.</p><br/><br/>View the original <a href='https://www.accessnewswire.com/newsroom/en/biotechnology/ascendiant-capital-markets-raises-igc-pharma-price-target-to-5.25-citing-clinical-pro-1155969'>press release</a> on ACCESS Newswire<br/><br/>
      <img src="https://app.accessnewswire.com/img.ashx?id=1155969" width="0" height="0"/>

Ascendiant Capital Markets has raised IGC Pharma's price target to $5.25, citing expected positive clinical data for IGC-AD1 in Alzheimer's trials. This potential catalyst could drive investor interest and stock performance throughout 2026 as the company progresses with its innovative therapies.

Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News